טוען...
CYP3A5 genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation
PURPOSE: Liver transplantation is the treatment of choice for patients with end-stage liver disease. Due to the between- and within-individual pharmacokinetic variability in tacrolimus, used to prevent rejection after transplantation, it is difficult to predict the dose needed achieve the target lev...
שמור ב:
| הוצא לאור ב: | Ther Clin Risk Manag |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6207397/ https://ncbi.nlm.nih.gov/pubmed/30498355 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S184376 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|